PG
PGIM India Healthcare Fund Direct Growth
Latest NAV
+25.67% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
0.93%
AUM
₹125 Cr
Min SIP
₹1,000
Min lump sum
₹5,000
1Y
+25.67%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Dec 2024
Where the NAV sits & how risky it is
₹12.11
52-week range
at 81%
₹12.11
Low 28 Mar 2025₹9.42
High 31 Aug 2026₹12.75
Risk level
Very High
Low
Very high
NAV history
11 Dec 2024
Since inception
05 Oct 2026
Returns by period
1W
-2.86%
1M
-2.78%
3M
+5.70%
6M
+25.15%
1Y
+25.67%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹1,000
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 97.90%
Cash & other 2.10%
Sector split
Country split
Top 5 hold 40.3%
Top 10 hold 62.6%
30 equity holdings
Equity holdings
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
11.34%
|
+4.97% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
10.01%
|
+4.11% |
| 3 | J B Chemicals and Pharmaceuticals
INE572A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.53%
|
+25.00% |
| 4 | Aster DM Healthcare
INE914M01019 |
Healthcare Medical Care Facilities |
India |
6.44%
|
+32.41% |
| 5 | Rubicon Research
INE506V01022 |
Healthcare Drug Manufacturers - General |
India |
5.97%
|
+88.81% |
| 6 | Mankind Pharma
INE634S01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.24%
|
+8.02% |
| 7 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
4.97%
|
-3.40% |
| 8 | Ajanta Pharma
INE031B01049 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.68%
|
+13.53% |
| 9 | Krishna Institute of Medical Sciences
INE967H01025 |
Healthcare Medical Care Facilities |
India |
4.15%
|
+25.76% |
| 10 | Dr. Lal Path Labs
INE600L01024 |
Healthcare Diagnostics & Research |
India |
3.27%
|
+7.72% |
About this scheme
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns
Fund manager(s): Puneet Pal, Vivek Sharma, Anandha Padmanabhan Anjen, Utsav Mehta
Exit load: Exit load of 0.50%, if redeemed within 90 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
06 Dec 2024
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 95.9 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 7.7 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 4.9 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 4.9 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 3.6 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 3.5 pts ahead of this fund